You are here

PHARMAIN CORPORATION

Company Information
Address
11812 N CREEK PKWY N STE 101
BOTHELL, WA 98011-8202
United States


https://www.pharmain.com

Information

UEI: G1NAHNEAVKK9

# of Employees: 12


Ownership Information

HUBZone Owned: No

Socially and Economically Disadvantaged: No

Woman Owned: No



Award Charts




Award Listing

  1. Vasoactive intestinal peptide for the treatment of psoriasis

    Amount: $372,133.00

    DESCRIPTION (provided by applicant): Psoriasis is a chronic inflammatory skin disease that to this date is only insufficiently controlled by currently available treatments which can also come with sev ...

    SBIRPhase I2012Department of Health and Human Services National Institutes of Health
  2. Nanocarrier-formulated NF-kB inhibitors for Inflammatory diseases

    Amount: $599,949.00

    DESCRIPTION (provided by applicant): Despite the success of TNF-inhibitors and other new biological drugs for the treatment of autoimmune and other chronic inflammatory diseases, there are still many ...

    SBIRPhase I2011Department of Health and Human Services National Institutes of Health
  3. Nanocarrier-formulated anti-fibrotic peptides for cirrhosis- Fast Track SBIR

    Amount: $782,928.00

    DESCRIPTION (provided by applicant): This application pertains to the development of Medication for Hepatic Fibrosis. Established cirrhosis has a 10-year mortality of 34-66%, largely dependent on the ...

    SBIRPhase II2010Department of Health and Human Services National Institutes of Health
  4. Outpatient treatment for portal hypertension

    Amount: $223,422.00

    DESCRIPTION (provided by applicant): Portal hypertension (increased pressure in the portal venous system) is one of the main consequences of cirrhosis. Although the reduction of portal hypertension is ...

    SBIRPhase I2010Department of Health and Human Services National Institutes of Health
  5. Nanocarrier-formulated anti-fibrotic peptides for cirrhosis- Fast Track SBIR

    Amount: $160,363.00

    DESCRIPTION (provided by applicant): This application pertains to the development of Medication for Hepatic Fibrosis. Established cirrhosis has a 10-year mortality of 34-66%, largely dependent on the ...

    SBIRPhase I2010Department of Health and Human Services National Institutes of Health
  6. EGF/Gastrin for islet cell regeneration

    Amount: $443,608.00

    DESCRIPTION (provided by applicant): New therapies are desperately needed to relieve patients with Type 1 diabetes from the neuropathy, nephropathy and retinopathy associated with the current standard ...

    SBIRPhase I2009Department of Health and Human Services National Institutes of Health
  7. Long-acting VIP formulations for the treatment of chronic inflammatory diseases

    Amount: $600,000.00

    DESCRIPTION (provided by applicant): Despite the success of TNF-inhibitors and other new biological drugs for the treatment of autoimmune and other chronic inflammatory diseases, there are still many ...

    SBIRPhase I2009Department of Health and Human Services National Institutes of Health
  8. Nanocarrier with metal bridge for affinity based delivery of metal binding peptid

    Amount: $383,625.00

    DESCRIPTION (provided by applicant): Lysostaphin, a metalloendopeptidase that is bacteriolytic for Staphylococcus aureus, is a potential systemic therapy for treating multidrug-resistant S. aureus med ...

    SBIRPhase I2008Department of Health and Human Services National Institutes of Health
  9. Long Acting Native GLP-1 formulations for Type 1 Diabetes

    Amount: $914,882.00

    DESCRIPTION (provided by applicant): New therapies are desperately needed to relieve patients with Type 1 diabetes from the neuropathy, nephropathy and retinopathy associated with the current standard ...

    SBIRPhase II2007Department of Health and Human Services National Institutes of Health
  10. Targeted formulations of GLP-1 for Type 1 diabetes

    Amount: $1,000,600.00

    DESCRIPTION (provided by applicant): New therapies are desperately needed for patients with Type 1 diabetes. Recent reports that the insulin-stimulating hormone Glucagon-Like Peptide (GLP-1), can i ...

    SBIRPhase I2004Department of Health and Human Services National Institutes of Health
US Flag An Official Website of the United States Government